7 completed, 3 terminated, 1 unknown. 7 Phase 2, 4 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Terminated 3, Unknown 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 4 | 1 | Completed 1 |
Follow volociximab: new trials by email Literature Review of volociximab trials Research Report on volociximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serum Serotonin and Pruritus After Intrathecal Morphine in Cesarean Section Morphine 100 μg, Morphine 200 μg - Pruritus | Phase 4 | Completed | Assiut University | 40 | 2014-04-02 | 2017-07-06 |
| A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration volociximab - Age-related Macular Degeneration | Phase 1 | Completed | Ophthotech Corporation | 63 | 2008-10-01 | 2024-02-21 |
| A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC) M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab - Non-small Cell Lung Cancer | Phase 1 | Completed | Abbott | 7 | 2008-04-01 | 2012-04-27 |
| A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC) M200 (Volociximab), Carboplatin, Paclitaxel - Non-small Cell Lung Cancer | Phase 1 | Completed | AbbVie | 33 | 2007-12-01 | 2017-11-21 |
| A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Volociximab - Ovarian Cancer, Peritoneal Neoplasms | Phase 2 | Terminated | Facet Biotech | 16 | 2007-08-01 | 2012-08-23 |
| Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) M200 (Volociximab), Liposomal Doxorubicin - Ovarian Cancer, Primary Peritoneal Cancer | Phase 1 / Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 138 | 2007-07-01 | 2013-01-18 |
| A Study of Volociximab in Metastatic Melanoma volociximab - Stage IV Melanoma | Phase 2 | Terminated | Abbott | 19 | 2006-12-01 | 2012-04-27 |
| Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer volociximab, erlotinib hydrochloride - Lung Cancer | Phase 2 | Unknown | Jonsson Comprehensive Cancer Center | 2005-07-01 | 2013-12-19 | |
| A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer Volociximab, Gemcitabine - Pancreatic Cancer | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 40 | 2005-03-01 | 2013-01-30 |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) Volociximab (anti-α5β1 integrin monoclonal antibody) - Renal Cell Carcinoma, Metastases | Phase 2 | Terminated | Abbott | 48 | 2005-01-01 | 2012-04-27 |
| Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy M200 (volociximab) in Combination with Dacarbazine (DTIC) - Melanoma, Metastases | Phase 2 | Completed | PDL BioPharma, Inc. | 40 | 2004-12-01 | 2008-08-05 |
Carcinoma (4) · Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Melanoma (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Lung Neoplasms (1) · Macular Degeneration (1) · Pancreatic Neoplasms (1) · Peritoneal Neoplasms (1) · Pruritus (1)
Abbott (3) · AbbVie (prior sponsor, Abbott) (2) · AbbVie (1) · Assiut University (1) · Facet Biotech (1) · Jonsson Comprehensive Cancer Center (1) · Ophthotech Corporation (1) · PDL BioPharma, Inc. (1)
United States (8) · Australia (1) · Belgium (1) · Canada (1) · Italy (1) · Poland (1) · Russia (1) · Spain (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Mihail Obrocea, MD (6) · Agop Y. Bedikian, MD (1) · Andres Forero, M.D. (1) · Antoni Ribas, MD (1) · C. William Helm, MD (1) · Carolyn Matthews, MD (1) · Colin P. Curran, M.D. (1) · Dana Glenn, MD (1) · Deborah Armstrong, MD (1) · Eric Winquist, MD (1) · Ernst Lengyel, MD (1) · James Burke, MD (1) · John Glaspy, MD (1) · John Kirkwood, M.D. (1) · Krish Tewari, MD (1)